Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ETCompany ParticipantsBen R.

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based company said it had ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.